

Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on May 28, 2026 | For discussion with your oncologist

TRIAL

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

NCT ID: NCT04729543 Phase: PHASE1 / PHASE2 Sponsor: Erasmus Medical Center Status: Recruiting

SUMMARY

Single-centre, first-in-man phase I/II trial to demonstrate safety and efficacy of MAGE-C2/HLA-A2 TCR T cells (MC2 TCR T cells) in advanced melanoma (MEL) and head-and-neck carcinoma (HNSCC).

KEY ELIGIBILITY CRITERIA

- 1. Written informed consent;
- 2. Age ≥ 18 years;
- 3. One of the following three malignancies:
 - * Previously treated for unresectable or metastatic cutaneous or mucosal melanoma for whom no standard treatment is available (anymore);
 - * Metastatic uveal melanoma, progressing after standard of care therapy, if available;
 - * R/M HNSCC for whom no standard treatment is available anymore;
- 4. Patients must be HLA-A2*0201 positive;
- 5. Primary tumor and/or metastasis (archival or fresh biopsy) is positive for MC2 (>5% of tumor cells) according to immunohistochemistry;
- 6. Measurable disease according to RECIST v1.1;
- 7. At least one lesion, suitable for sequential mandatory tumor biopsies;

ENROLLMENT CONTACT

A.A.M. van der Veldt, MD, PhD

Erasmus Medical Center

Rotterdam, Netherlands

Phone: +31 107041754

Email: a.vanderveldt@erasmusmc.nl

Total sites: 1 | 1 currently recruiting